What is the recommended management for atherosclerosis?

Management of Atherosclerosis

For patients with established atherosclerotic cardiovascular disease (ASCVD), initiate high-intensity statin therapy (atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily) immediately, targeting LDL-C <55 mg/dL (<1.4 mmol/L) with at least a 50% reduction from baseline. 1

Lipid-Lowering Therapy Algorithm

Step 1: Initial Treatment

• Start high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for all patients with ASCVD 1, 2
• If baseline LDL-C is very high, consider upfront combination therapy with statin + ezetimibe 1
• For patients with diabetes or metabolic syndrome, consider pitavastatin with ezetimibe (reduces new-onset diabetes risk) or lower-dose high-intensity statin (rosuvastatin 20 mg or atorvastatin 40 mg) plus ezetimibe 1

Step 2: Reassess at 4-6 Weeks

• If LDL-C remains >55 mg/dL (>1.4 mmol/L), immediately add ezetimibe to statin therapy 1, 2
• Ezetimibe reduces LDL-C by an additional 20-25% 2

Step 3: Reassess at Another 4-6 Weeks

• If LDL-C still >55 mg/dL (>1.4 mmol/L), add PCSK9 inhibitor (alirocumab or evolocumab subcutaneously every 2-4 weeks, or inclisiran every 6 months) 1, 3
• PCSK9 inhibitors reduce major adverse cardiovascular events (MACE) by 26% and major adverse limb events (MALE) in peripheral artery disease 3

Step 4: Extremely High-Risk Patients

• For patients experiencing a second vascular event within 2 years while on maximum tolerated statin therapy, target LDL-C <40 mg/dL (<1.0 mmol/L) 2

Statin Intolerance

• Use ezetimibe as first-line therapy 2
• Add bempedoic acid if LDL-C goal not achieved on ezetimibe 3
• Consider PCSK9 inhibitor if still not at goal 3

Antiplatelet Therapy

For Acute Coronary Syndrome or Recent Stroke

• Dual antiplatelet therapy (DAPT) for up to 90 days, then transition to single antiplatelet agent 4
• Aspirin 75-325 mg daily is recommended for all patients with atherosclerosis 5

For Severe Intracranial Stenosis (70-99%)

• DAPT for up to 90 days followed by single antiplatelet agent 4

Blood Pressure Management

• Target <140/90 mm Hg for neurologically stable patients 6, 4
• Target <130/80 mm Hg for most patients with ASCVD 6
• Target <120 mm Hg systolic for high-risk individuals 7
• Preferentially use thiazide diuretics, ACE inhibitors, or ARBs 4
• Beta-blockers and/or ACE inhibitors are first-line for patients with blood pressure ≥140/90 mm Hg 6

Diabetes Management

• Target HbA1c <7% for most patients 6, 4
• Use SGLT2 inhibitors or GLP-1 receptor agonists preferentially (proven cardiovascular benefits) 3, 7
• Add metformin and other glucose-lowering agents as needed 3

Lifestyle Modifications

Physical Activity

• Minimum 10 minutes of moderate-intensity aerobic activity 4 times weekly for capable patients 4
• Standard recommendation: 150 minutes/week moderate-intensity or 75 minutes/week vigorous-intensity activity 7

Diet

• Saturated fat <7% of total calories 8, 6, 9
• Cholesterol <200 mg/day 8, 9
• Trans fat <1% of total calories 8, 9
• Add soluble fiber 10-25 g/day 8, 6
• Add plant stanols/sterols 2 g/day 8, 6, 9

Weight Management

• Target 5-10% body weight reduction 7
• Consider pharmacological weight management for BMI ≥30 kg/m² (or ≥27 kg/m² with ASCVD risk factors) 7

Smoking Cessation

• Complete and persistent abstinence from all tobacco products 1, 7
• Assess tobacco use at every visit 6
• Provide counseling and pharmacotherapy at every visit 6

Special Considerations

Triglycerides

• If triglycerides 200-499 mg/dL, target non-HDL-C <130 mg/dL 8, 9
• If triglycerides >500 mg/dL, add fibrate therapy to prevent acute pancreatitis 6
• Consider niacin or fibrate after LDL-C lowering for triglycerides >200 mg/dL 8, 9

Abdominal Aortic Aneurysm (AAA)

• Statins should be considered to reduce AAA growth rate and rupture risk 3
• Evidence is mixed but most patients with AAA have cardiovascular risk factors warranting liberal lipid-lowering therapy 3

Monitoring and Follow-Up

• Reassess LDL-C every 4-6 weeks during treatment escalation 1
• Once at goal, monitor regularly with telemonitoring, e-visits, or in-person visits 1
• Provide standardized discharge instructions with specific LDL-C goals and escalation plans 1

Critical Pitfalls to Avoid

1. Do not delay treatment escalation – if LDL-C is not at goal after 4-6 weeks, immediately add the next agent rather than waiting 1
2. Do not use moderate-intensity statins in ASCVD patients who can tolerate high-intensity therapy 10, 2
3. Do not stop at monotherapy – most patients require combination therapy to reach LDL-C <55 mg/dL 1
4. Do not neglect non-lipid risk factors – blood pressure, diabetes, smoking cessation, and lifestyle modifications are equally critical 1, 6
5. Do not use statins during pregnancy or when pregnancy is planned 2